Document is current
Any future updates will be listed below
-
Authors
Rämö, Joel T. https://orcid.org/0000-0002-6429-5149
Gorman, Bryan R. https://orcid.org/0000-0002-4239-4672
Weng, Lu-Chen
Jurgens, Sean J. https://orcid.org/0000-0002-1605-9782
Singhanetr, Panisa
Tieger, Marisa G.
van Dijk, Elon HC
Halladay, Christopher W.
Wang, Xin https://orcid.org/0000-0002-0322-8970
Hauser, Blake M.
Kim, Soo Hyun https://orcid.org/0000-0003-4037-6988
Brinks, Joost https://orcid.org/0000-0002-2649-8199
Choi, Seung Hoan
Luo, Yuyang
,
,
Pyarajan, Saiju https://orcid.org/0000-0002-9047-3762
Nealon, Cari L. https://orcid.org/0000-0002-6997-2743
Gorin, Michael B. https://orcid.org/0000-0001-9498-7982
Wu, Wen-Chih https://orcid.org/0000-0002-2834-2024
Anthony, Scott A.
Roncone, David P.
Sobrin, Lucia
Kaarniranta, Kai
Yzer, Suzanne
Palotie, Aarno https://orcid.org/0000-0002-2527-5874
Peachey, Neal S. https://orcid.org/0000-0002-4419-7226
Turunen, Joni A. https://orcid.org/0000-0002-9569-9146
Boon, Camiel JF
Ellinor, Patrick T.
Iyengar, Sudha K. https://orcid.org/0000-0001-7488-250X
Daly, Mark J.
Rossin, Elizabeth J. https://orcid.org/0000-0002-0052-9575
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K12EY016335, 1K23EY035342)
- License Information
-
More Information
Article History
Received: 13 May 2024
Accepted: 28 March 2025
First Online: 3 May 2025
Competing interests
: Dr. Rossin and Dr. Rämö are named inventors on a provisional patent application that describes the secondary use of intravitreal Anti-Ang2 medications for use in the treatment of central serous chorioretinopathy. Dr. Ellinor receives sponsored research support from Bayer AG, IBM Research, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for MyoKardia and Bayer AG. The remaining authors declare no competing interests.
